Automated cell therapy manufacturing attracts $1.1B across 34 rounds, led by Cellares
What's the deal? Companies automating cell therapy manufacturing have collectively raised nearly $1.1 billion across 34 funding rounds, according to a new report from market intelligence platform TracxnDealroom has a profile for this one. Try Dealroom →.
The report tracked 23 companies across 11 countries building platforms for advanced therapies like CAR-T, natural killer (NK), and stem cell-derived treatments.
Two players dominate. Cellares ($612 million) and Ori Biotech ($281 million) account for roughly 81% of all disclosed equity funding; the other 21 companies share just $205 million.
Why now? The sector is shifting from labour-intensive production to industrialised, scalable manufacturing — and investor appetite is following.
After moderating in 2024, funding rebounded sharply in 2026, with $260 million raised through April alone.
Cellares' latest round drew major institutional names, including BlackRock, T. Rowe Price, Baillie Gifford, Gates FrontierDealroom has a profile for this one. Try Dealroom →, Intuitive Surgical, and EDBIDealroom has a profile for this one. Try Dealroom →.
Regulation is another tailwind. Both leaders won the US Food and Drug Administration's Advanced Manufacturing Technology (AMT) designation in 2025, clearing a faster path to commercial-scale production.
What could go wrong? The capital is dangerously concentrated. With two firms holding 81% of funding, smaller innovators are being squeezed.
Seed-stage companies have raised only $38 million across 15 rounds, pointing to a persistent gap for emerging players.
As of April 2026, Cellares and Ori Biotech remain the only firms combining commercial-scale GMP manufacturing with AMT designation — a moat that could harden into a duopoly.
The signal: Both Cellares and Ori Biotech are now late-stage companies, and the crossover investors backing them — BlackRock, T. Rowe Price, and Baillie Gifford — typically position ahead of a public listing, suggesting the sector's leaders are being primed for IPO-scale exits. The presence of strategic backers like Intuitive Surgical hints that automated cell therapy manufacturing is increasingly viewed as adjacent infrastructure by established medtech players.
Read more: Indian Pharma Post
